#USA #Scientia Vascular #John Lippert #Rick Randall #West Valley City, Utah

Scientia Vascular Announces Leadership Transition

In a strategic shift that highlights its commitment to innovation and growth in the neurovascular medical field, Scientia Vascular has announced a significant leadership change. Effective January 13, 2025, CEO John Lippert will transition to the Chief Technology Officer (CTO) role, while Rick Randall has been appointed as the new CEO and Chairman of the Board.

A Visionary Shift

John Lippert, the founder of Scientia Vascular, has played a pivotal role in positioning the company as an industry leader in neurovascular solutions. Under his stewardship, the company has transformed from a startup into a key player in neurointerventional technology, renowned for pioneering advancements in medical devices aimed at improving patient outcomes.

As he steps into the CTO role, Lippert will focus on spearheading the development of next-generation therapies and solutions that address critical gaps in neurovascular care. His deep understanding of the industry and his commitment to innovation will remain crucial as he dedicates his efforts to enhancing the company's product offerings.

Rick Randall: A New Era of Leadership

Rick Randall brings over 35 years of invaluable experience in the medical device sector to this new role. His journey in the industry includes significant leadership positions at various neuro-focused organizations, where he has successfully guided businesses through public offerings as well as mergers and acquisitions. Randall's previous experience as CEO of Target Therapeutics allowed him to make a substantial impact, leading the company to become the first neurointerventional firm to go public, alongside developing groundbreaking technologies.

Randall's appointment is seen as a strategic move to amplify Scientia's growth trajectory. His expertise in commercialization and strategic planning will be key as the company expands its market presence and brings new medical products to fruition.

Lippert shared his enthusiasm about the transition, stating, "Rick's leadership will be instrumental in expanding our sales efforts and heading our new marketing initiatives. We are optimistic that with Randall at the helm, and alongside our immensely talented executive team, Scientia Vascular is poised to navigate towards a promising future dedicated to advancing patient care."

Focus on Patient-Centric Innovation

Upon his appointment, Randall expressed his eagerness to be part of Scientia Vascular. He emphasized the unique positioning of Scientia within the rapidly evolving landscape of the interventional stroke treatment sector. "Scientia's next-generation vascular access technology is perfectly attuned to the growing demands in this field. I am excited to collaborate with the team as we continue to innovate and transform how neurovascular conditions are treated," he stated.

The leadership transition comes at an exciting time for Scientia Vascular, reinforcing its dedication to enhancing patient outcomes through advanced medical devices. Lippert will now concentrate on leveraging his experience to develop cutting-edge patient solutions, ensuring that the company's innovations continue to push the boundaries of what's possible in treating neurovascular diseases.

With Rick Randall and John Lippert now at the forefront of Scientia's strategic vision, the company is set to strengthen its position in the medical device arena and remains committed to its mission of enhancing patient care in the neurovascular space.

For inquiries, please contact Larry Myres, Chief Operating Officer and President of Scientia Vascular, at [email protected] or call 760.889.4649.

About Scientia Vascular

Scientia Vascular is a leading innovator dedicated to improving patient care by advancing the design and manufacturing of medical solutions that push the boundaries in the treatment of brain-related diseases. The company is committed to developing cutting-edge technologies that enhance patient outcomes and expand the possibilities within neurovascular intervention.